Pirro, Valentina
Eli Lilly (United States)
4 papers on CoChatORCID 0000-0002-3924-6943
Most cited papers
- Verified
LY3437943, a novel triple glucagon, GIP, and GLP-1 receptor agonist for glycemic control and weight loss: From discovery to clinical proof of concept.
Coskun, T., Urva, S., Roell, W. C., Qu, H., Loghin, C., Moyers, J. S., O’Farrell, L. S., Briere, D. A., Sloop, K. W., Thomas, M. K., et al. (2022) · Cell Metabolism
Diabetes Treatment and ManagementPharmacology and Obesity Treatment
Cited by 316
- Verified
GIPR agonism mediates weight-independent insulin sensitization by tirzepatide in obese mice
Samms, R. J., Christe, M. E., Collins, K. A. L., Pirro, V., Droz, B. A., Holland, A. K., Friedrich, J. L., Wojnicki, S., Konkol, D. L., Cosgrove, R., et al. (2021) · Journal of Clinical Investigation
Diabetes Treatment and ManagementAdipokines, Inflammation, and Metabolic Diseases
Cited by 256
- Verified
Tirzepatide induces a thermogenic-like amino acid signature in brown adipose tissue
Samms, R. J., Zhang, G., He, W., Ilkayeva, O., Droz, B. A., Bauer, S. M., Stutsman, C., Pirro, V., Collins, K. A., Furber, E. C., et al. (2022) · Molecular Metabolism
Adipose Tissue and MetabolismAdipokines, Inflammation, and Metabolic Diseases
Cited by 93
- Verified
Treatment with orforglipron, an oral glucagon-like peptide-1 receptor agonist, is associated with improvements of CV risk biomarkers in participants with type 2 diabetes or obesity without diabetes
Wharton, S., Rosenstock, J., Konige, M., Lin, Y., Duffin, K., Wilson, J., Banerjee, H., Pirro, V., Kazda, C., & Mather, K. (2025) · Cardiovascular Diabetology
Diabetes Treatment and ManagementDiabetes, Cardiovascular Risks, and Lipoproteins
Cited by 26
Go further with a free account
Verify every reference, keep papers in a library, and ask questions across them.
Sign up - it is free